Role of oral teriflunomide in the management of multiple sclerosis [PDF]
Neuropsychiatric Disease and Treatment, 2013 Radu Tanasescu,1,2 Nikos Evangelou,1 Cris S Constantinescu1 1Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK; 2Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest ...
Tanasescu R +2 more
doaj +5 more sources
Role of Diet and Supplementation with Omega-3 Polyunsaturated Fatty Acids for Managing Chronic Fatigue in Patients with Relapsing-Remitting Multiple Sclerosis [PDF]
Journal of Biomedical & Clinical Research, 2022 Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS) with unclear and multifactorial etiology, variable clinical symptoms with different severity, and treatment with limited efficacy.
Nicholas Shepherd +5 more
doaj +3 more sources
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis
Frontiers in Immunology, 2023 ObjectivesRecent studies supported coagulation involvement in multiple sclerosis, an inflammatory-demyelinating and degenerative disease of the central nervous system. The main objectives of this observational study were to identify the most specific pro-
Tatiana Koudriavtseva +21 more
doaj +1 more source
Positive correlation between functional disability, excessive daytime sleepiness, and fatigue in relapsing-remitting multiple sclerosis [PDF]
Arquivos de Neuro-Psiquiatria, 2016 Sleep disorders in patients with multiple sclerosis have various causes and interfere with daytime wakefulness. This study assessed the correlation between fatigue, excessive daytime sleepiness and level of disability.
Douglas Martins Braga +3 more
doaj +4 more sources
Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients. [PDF]
PLoS ONE, 2012 Interferon-β is a first-line therapy used to prevent relapses in relapsing-remitting multiple sclerosis. The clinical benefit of interferon-β in relapsing-remitting multiple sclerosis is attributed to its immunomodulatory effects on inflammatory ...
Nicolas Molnarfi +4 more
doaj +1 more source
Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
Medicine Advances, 2023 Background Ofatumumab is the first monoclonal antibody developed specifically for treating relapsed multiple sclerosis (RMS). This disease (Multiple Sclerosis) includes relapsing–remitting multiple sclerosis (RRMS), a chronic autoimmune illness that ...
Peter Olujimi Odutola +7 more
doaj +1 more source
Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. [PDF]
PLoS ONE, 2016 Conduction along the optic nerve is often slowed in multiple sclerosis (MS). This is typically assessed by measuring the latency of the P100 component of the Visual Evoked Potential (VEP) using electroencephalography.
Hanni S M Kiiski +15 more
doaj +1 more source
Frontiers in Neuroscience, 2021 ObjectiveTo characterize microstructural white matter changes related to relapsing-remitting multiple sclerosis using advanced diffusion MRI modeling and tractography.
Ann-Marie Beaudoin +6 more
doaj +1 more source
Primary progressive multiple sclerosis in the Polish population
Aktualności Neurologiczne, 2017 Objectives: The aim of the study was the epidemiological analysis and evaluation of selected clinical and sociodemographic factors in Polish patients with primary progressive multiple sclerosis.
Waldemar Brola +4 more
doaj +1 more source
Multiple Sclerosis Relapsing Remitting Progressive Type
Jurnal Profesi Medika, 2020 Multiple sclerosis (MS) is the most common neurologic demyelinating disease in high-income countries. The causes of MS is multifactorial involve genetics and the environment in which immune cell infiltration occurs across the blood-brain barrier, causing
Nora Fitri +2 more
doaj +1 more source